Medicenna Therapeutics Corp Stock Probability of Future Stock Price Finishing Over 6.83
| MDNA Stock | CAD 1.57 0.08 5.37% |
Medicenna |
Medicenna Therapeutics Target Price Odds to finish over 6.83
The tendency of Medicenna Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over C$ 6.83 or more in 90 days |
| 1.57 | 90 days | 6.83 | close to zero percent |
Based on a normal probability distribution, the odds of Medicenna Therapeutics to move over C$ 6.83 or more in 90 days from now is close to zero percent (This Medicenna Therapeutics Corp probability density function shows the probability of Medicenna Stock to fall within a particular range of prices over 90 days) . Probability of Medicenna Therapeutics price to stay between its current price of C$ 1.57 and C$ 6.83 at the end of the 90-day period is about 98.0 .
Assuming the 90 days trading horizon Medicenna Therapeutics Corp has a beta of -0.5. This indicates as returns on the benchmark increase, returns on holding Medicenna Therapeutics are expected to decrease at a much lower rate. During a bear market, however, Medicenna Therapeutics Corp is likely to outperform the market. Additionally Medicenna Therapeutics Corp has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Medicenna Therapeutics Price Density |
| Price |
Predictive Modules for Medicenna Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Medicenna Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Medicenna Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Medicenna Therapeutics is not an exception. The market had few large corrections towards the Medicenna Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Medicenna Therapeutics Corp, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Medicenna Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.32 | |
β | Beta against Dow Jones | -0.5 | |
σ | Overall volatility | 0.26 | |
Ir | Information ratio | -0.1 |
Medicenna Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Medicenna Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Medicenna Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Medicenna Therapeutics generated a negative expected return over the last 90 days | |
| Medicenna Therapeutics has high historical volatility and very poor performance | |
| Medicenna Therapeutics may become a speculative penny stock | |
| Medicenna Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (25.47 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Medicenna Therapeutics Corp has accumulated about 33.6 M in cash with (16.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.83. | |
| Roughly 22.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Medicennas MDNA11 Drug Shows 30 percent Response Rate, Strong Results in Cancer Trial MDNAF Stock News - StockTitan |
Medicenna Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Medicenna Stock often depends not only on the future outlook of the current and potential Medicenna Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Medicenna Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 69.6 M | |
| Cash And Short Term Investments | 17 M |
Medicenna Therapeutics Technical Analysis
Medicenna Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Medicenna Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Medicenna Therapeutics Corp. In general, you should focus on analyzing Medicenna Stock price patterns and their correlations with different microeconomic environments and drivers.
Medicenna Therapeutics Predictive Forecast Models
Medicenna Therapeutics' time-series forecasting models is one of many Medicenna Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Medicenna Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Medicenna Therapeutics
Checking the ongoing alerts about Medicenna Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Medicenna Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Medicenna Therapeutics generated a negative expected return over the last 90 days | |
| Medicenna Therapeutics has high historical volatility and very poor performance | |
| Medicenna Therapeutics may become a speculative penny stock | |
| Medicenna Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (25.47 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Medicenna Therapeutics Corp has accumulated about 33.6 M in cash with (16.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.83. | |
| Roughly 22.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Medicennas MDNA11 Drug Shows 30 percent Response Rate, Strong Results in Cancer Trial MDNAF Stock News - StockTitan |
Other Information on Investing in Medicenna Stock
Medicenna Therapeutics financial ratios help investors to determine whether Medicenna Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medicenna with respect to the benefits of owning Medicenna Therapeutics security.